These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626 [TBL] [Abstract][Full Text] [Related]
26. [Perhaps an explanation for the therapeutic escape of prostate cancer treated with antiandrogens]. Jeanteur P Bull Cancer; 2000 Jul; 87(7-8):524-5. PubMed ID: 10969205 [No Abstract] [Full Text] [Related]
27. [Anti-apoptotic effect of the androgen receptor in human prostate cancer]. Shen FY; Li BY Zhonghua Nan Ke Xue; 2007 Dec; 13(12):1121-4. PubMed ID: 18284065 [TBL] [Abstract][Full Text] [Related]
28. Mechanisms of prostate cancer cell survival after inhibition of AR expression. Cohen MB; Rokhlin OW J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258 [TBL] [Abstract][Full Text] [Related]
29. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells. Gunawardena K; Campbell LD; Meikle AW Cancer Detect Prev; 2005; 29(4):389-95. PubMed ID: 16139439 [TBL] [Abstract][Full Text] [Related]
30. A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Jackson TL Neoplasia; 2004; 6(6):697-704. PubMed ID: 15720795 [TBL] [Abstract][Full Text] [Related]
32. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Linja MJ; Savinainen KJ; Saramäki OR; Tammela TL; Vessella RL; Visakorpi T Cancer Res; 2001 May; 61(9):3550-5. PubMed ID: 11325816 [TBL] [Abstract][Full Text] [Related]
33. Primary combined androgen blockade in localized disease and its mechanism. Namiki M; Kitagawa Y; Mizokami A; Koh E Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):303-15. PubMed ID: 18471788 [TBL] [Abstract][Full Text] [Related]
34. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]
35. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261 [TBL] [Abstract][Full Text] [Related]
36. Evolution of the androgen receptor pathway during progression of prostate cancer. Hendriksen PJ; Dits NF; Kokame K; Veldhoven A; van Weerden WM; Bangma CH; Trapman J; Jenster G Cancer Res; 2006 May; 66(10):5012-20. PubMed ID: 16707422 [TBL] [Abstract][Full Text] [Related]
37. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Srinivasan S; Ranga RS; Burikhanov R; Han SS; Chendil D Cancer Res; 2007 Jan; 67(1):246-53. PubMed ID: 17185378 [TBL] [Abstract][Full Text] [Related]
38. Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy. Röpke A; Erbersdobler A; Hammerer P; Palisaar J; John K; Stumm M; Wieacker P Prostate; 2004 Apr; 59(1):59-68. PubMed ID: 14991866 [TBL] [Abstract][Full Text] [Related]
39. Androgen receptor gene mutations in hormone-refractory prostate cancer. Wallén MJ; Linja M; Kaartinen K; Schleutker J; Visakorpi T J Pathol; 1999 Dec; 189(4):559-63. PubMed ID: 10629558 [TBL] [Abstract][Full Text] [Related]